Overview

• Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD will operate as standalone companies under Sycamore ownership.
• Retail veteran Mike Motz was appointed CEO, John Lederer became executive chairman, and former chief executive Tim Wentworth moved to the board.
• Walgreens stock will cease trading following shareholder approval, with holders set to receive $11.45 in cash plus up to $3 per share tied to future VillageMD monetization.
• Sycamore closed the deal in partnership with longtime Walgreens investor Stefano Pessina, whose family reinvested their entire stake.
• The restructuring follows sustained losses and debt tied in part to the VillageMD push, planned closures of roughly 1,200 U.S. stores, and recent internal cuts including July reductions to the media-buying team.